ArticleCancer discovery2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Open access · bronzeAbstract readCase Reports
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 1 synthesis or guideline pooled it, 207 citations in OpenAlex.
- Pooled it
- Evolving precision: Updates in targeted therapy for cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Review
- Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- [Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- The new era of AML therapy: current standards and emerging targets.International journal of clinical oncology · 2026Review
- Review
- Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies.Molecules (Basel, Switzerland) · 2026Review
- Review
- Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.Journal of personalized medicine · 2026Review
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.Journal of clinical medicine · 2026Review
- MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors.Cancer research communications · 2026Article
- Mitochondrial targets in IDH1-mutated cholangiocarcinoma.Hepatology communications · 2026Review
- Dynamic heterogeneity towards drug resistance in AML cells is primarily driven by epigenomic mechanism unveiled by multi-omics analysis.Journal of advanced research · 2026Article
- Preserved IDH mutation and methylation class in vorasidenib nonresponders: A report of 2 cases.Neuro-oncology practice · 2026Article
- Single-cell proteogenomic analysis of clonal evolution in PDX models of AML treated with IDH inhibitors.Blood neoplasia · 2026Article
- Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection ofInternational journal of molecular sciences · 2026Article
- State of the Art of IDH Inhibitors: Emerging Questions and Perspectives.Anti-cancer agents in medicinal chemistry · 2026Review
- Advances in the management of patients with IDH-mutant glioma.The oncologist · 2025Review
- Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.International journal of molecular sciences · 2025Review
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 3 institutions in 2 countries.
James J Harding *Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Maeve A Lowery *Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Alan H ShihDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Juan M SchvartzmanGastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-8036-1361
Shengqi HouHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Christopher FamulareCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Minal PatelCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Mikhail RoshalDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Richard K DoDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6554-0310
Ahmet ZehirCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5406-4104
Daoqi YouCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
S Duygu SelcukluCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Agnes VialeCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Martin S TallmanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
David M HymanDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ed ReznikDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6511-5947
Lydia W S FinleyCell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4023-7574
Elli PapaemmanuilCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
Alessandra TosoliniCelgene Corporation, Summit, New Jersey.
Mark G FrattiniCelgene Corporation, Summit, New Jersey.
Kyle J MacBethCelgene Corporation, Summit, New Jersey.
Guowen LiuAgios Pharmaceuticals, Inc., Cambridge, Massachusetts.
Bin FanAgios Pharmaceuticals, Inc., Cambridge, Massachusetts.
Sung ChoeAgios Pharmaceuticals, Inc., Cambridge, Massachusetts.
Bin WuAgios Pharmaceuticals, Inc., Cambridge, Massachusetts.
Yelena Y JanjigianGastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Ingo K MellinghoffHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Luis A DiazDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ross L LevineDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ghassan K Abou-AlfaGastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1522-8054
Eytan M SteinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. intlekoa@mskcc.org steine@mskcc.org.
Andrew M IntlekoferDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. intlekoa@mskcc.org steine@mskcc.org.
Memorial Sloan Kettering Cancer Center · USAgios Pharmaceuticals (United States) · USBristol-Myers Squibb (Switzerland) · CH
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSynergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MMolecular Mechanisms of Drug Resistance in Primary Brain TumorsR35NS105109 · NINDS · SLOAN-KETTERING INST CAN RESEARCH · PI MELLINGHOFF, INGO K · 2018 to 2025
$4.7MAnalysis of TET2 function in acute leukemiaK08CA181507 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SHIH, ALAN · 2016 to 2020
$900kInvestigating L-2-hydroxyglutarate in normal hematopoiesis and leukemogenesisK08CA201483 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI INTLEKOFER, ANDREW MICHAEL · 2016 to 2020
$887kNCI NIH HHS K08 CA181507NCI NIH HHS K08 CA201483NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA197594NIH HHS U54 OD020355NINDS NIH HHS R35 NS105109
Abstract
Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase (
Indexed as
MutationAcute DiseaseAdenocarcinomaAgedDrug ResistanceEnzyme InhibitorsFemaleHumansIsocitrate DehydrogenaseIsoenzymesLeukemia, MyeloidLiver NeoplasmsMaleMiddle AgedMyelodysplastic SyndromesEnzyme InhibitorsIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseIsoenzymes
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.